| Jun 20 |
Sector Update: Health Care Stocks Higher Late Afternoon
|
| Jun 20 |
Gilead Stock Surges on Strong Results in HIV Drug Study
|
| Jun 20 |
Gilead Stock Gets Boost From HIV Drug Study Results
|
| Jun 20 |
S&P 500, Nasdaq 100 Dip From Record Highs As Investors Take Chipmaker Profits; Energy Sector Rebounds, Yields Rise: What's Driving Markets Thursday?
|
| Jun 20 |
Gilead Sciences' Twice-Yearly Shot Prevents 100% of HIV Cases in Trial, Shares Jump
|
| Jun 20 |
Gilead's Twice-Yearly Shot Prevents HIV
|
| Jun 20 |
Gilead Shot Prevents All HIV Cases in Trial of African Women
|
| Jun 20 |
Gilead gains on trial win for twice-yearly HIV PrEP therapy
|
| Jun 20 |
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention
|
| Jun 20 |
Twice-yearly shots of Gilead HIV drug effective in large prevention study
|
